BRPI0309534B8 - derivados de triazol como antagonistas do receptor de taquicinina, seu uso, e composição farmacêutica - Google Patents
derivados de triazol como antagonistas do receptor de taquicinina, seu uso, e composição farmacêuticaInfo
- Publication number
- BRPI0309534B8 BRPI0309534B8 BRPI0309534A BR0309534A BRPI0309534B8 BR PI0309534 B8 BRPI0309534 B8 BR PI0309534B8 BR PI0309534 A BRPI0309534 A BR PI0309534A BR 0309534 A BR0309534 A BR 0309534A BR PI0309534 B8 BRPI0309534 B8 BR PI0309534B8
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- receptor antagonists
- compound
- triazole derivatives
- tachykinin receptor
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- -1 their use Substances 0.000 title abstract 2
- 229940042055 systemic antimycotics triazole derivative Drugs 0.000 title 1
- 239000002462 tachykinin receptor antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000007124 Tachykinin Receptors Human genes 0.000 abstract 1
- 108010072901 Tachykinin Receptors Proteins 0.000 abstract 1
- 150000001335 aliphatic alkanes Chemical group 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
"composto, composição farmacêutica, e, uso de um composto". este relatório descritivo refere-se a um composto de fórmula ou um sal farmaceuticamente aceitável do mesmo, a composições farmacêuticas do mesmo, e a seu uso como inibidor do subtipo nk-1 de receptores de taquiquinina, e também a um processo para sua preparação, e intermediários para os mesmos. (1) em que: d é uma anel alcano c~ 1~-c~ 3~; r^ 1^ é fenila, que é opcionalmente substituído por de um a três substituintes selecionados independentemente do grupo que consiste de halo, alquila c~ 1~-c~ 4~, alcóxi c~ 1~-c~ 4~, ciano, difluorometila, trifluorometila, e trifluorometóxi: r^ 4^ é um radical selecionado do grupo que consiste de: (ia), (ib), (ic), (id), (ie), (if), (ig), (ih)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37612102P | 2002-04-26 | 2002-04-26 | |
| US60/376,121 | 2002-04-26 | ||
| PCT/US2003/010681 WO2003091226A1 (en) | 2002-04-26 | 2003-04-22 | Triazole derivatives as tachykinin receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR0309534A BR0309534A (pt) | 2005-02-01 |
| BRPI0309534B1 BRPI0309534B1 (pt) | 2017-11-07 |
| BRPI0309534B8 true BRPI0309534B8 (pt) | 2021-05-25 |
Family
ID=29270766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0309534A BRPI0309534B8 (pt) | 2002-04-26 | 2003-04-22 | derivados de triazol como antagonistas do receptor de taquicinina, seu uso, e composição farmacêutica |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US7320994B2 (pt) |
| EP (1) | EP1501809B1 (pt) |
| JP (1) | JP4559087B2 (pt) |
| KR (1) | KR100755577B1 (pt) |
| CN (1) | CN1312136C (pt) |
| AR (1) | AR039329A1 (pt) |
| AT (1) | ATE384053T1 (pt) |
| AU (1) | AU2003230829B8 (pt) |
| BR (1) | BRPI0309534B8 (pt) |
| CA (1) | CA2483159C (pt) |
| CR (1) | CR7548A (pt) |
| CY (1) | CY1107221T1 (pt) |
| DE (1) | DE60318697T2 (pt) |
| DK (1) | DK1501809T3 (pt) |
| EA (1) | EA007720B1 (pt) |
| EC (1) | ECSP045391A (pt) |
| ES (1) | ES2298513T3 (pt) |
| HR (1) | HRP20041008B1 (pt) |
| IL (2) | IL164675A0 (pt) |
| MX (1) | MXPA04010622A (pt) |
| MY (1) | MY141559A (pt) |
| NO (1) | NO333647B1 (pt) |
| NZ (1) | NZ535886A (pt) |
| PE (1) | PE20040600A1 (pt) |
| PL (1) | PL212090B1 (pt) |
| PT (1) | PT1501809E (pt) |
| TW (1) | TWI265807B (pt) |
| UA (1) | UA79113C2 (pt) |
| WO (1) | WO2003091226A1 (pt) |
| ZA (1) | ZA200408670B (pt) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| US20060160794A1 (en) * | 2003-06-12 | 2006-07-20 | Amegadzie Albert K | Tachykinin receptor antagonists |
| EA008881B1 (ru) | 2003-10-24 | 2007-08-31 | Эли Лилли Энд Компани | Новые кристаллические формы {2-[1-(3,5-бис-трифторметилбензил)-5-пиридин-4-ил-1h-[1,2,3]триазол-4-ил]пиридин-3-ил}-(2-хлорфенил)метанона |
| RU2007110731A (ru) | 2004-09-23 | 2008-10-27 | Редди Юс Терапевтикс | Новые соединения пиримидина, способ их получения и содержащие их композиции |
| WO2006083711A1 (en) * | 2005-02-01 | 2006-08-10 | Eli Lilly And Company | Tachykinin receptor antagonists |
| JP4874958B2 (ja) | 2005-03-30 | 2012-02-15 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピリジン誘導体を含有する抗真菌剤 |
| US8952176B2 (en) * | 2005-06-07 | 2015-02-10 | Shionogi & Co., Ltd. | Heterocyclic compound having type I 11 β hydroxysteroid dehydrogenase inhibitory activity |
| WO2007012579A1 (en) * | 2005-07-25 | 2007-02-01 | F. Hoffmann-La Roche Ag | Substituted triazole derivatives and their use as neurokinin 3 receptor antagonists |
| TWI385169B (zh) | 2005-10-31 | 2013-02-11 | Eisai R&D Man Co Ltd | 經雜環取代之吡啶衍生物及含有彼之抗真菌劑 |
| EP2054062A1 (en) * | 2006-08-18 | 2009-05-06 | Syngenta Limited | Use of hppd inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs |
| WO2008035726A1 (en) | 2006-09-21 | 2008-03-27 | Eisai R & D Management Co., Ltd. | Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same |
| DK2121610T3 (da) | 2006-12-20 | 2014-06-30 | Lilly Co Eli | Hidtil ukendt mellemprodukt og fremgangsmåde, som er anvendelige ved fremstilling af {2-[1-(3,5-bis-trifluormethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorphenyl)-methanon |
| AU2008285644A1 (en) | 2007-08-08 | 2009-02-12 | Neurosearch A/S | Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors |
| GB0722077D0 (en) * | 2007-11-09 | 2007-12-19 | Smithkline Beecham Corp | Compounds |
| US8513287B2 (en) | 2007-12-27 | 2013-08-20 | Eisai R&D Management Co., Ltd. | Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same |
| JP2011525915A (ja) * | 2008-06-26 | 2011-09-29 | アムジエン・インコーポレーテツド | キナーゼ阻害薬としてのアルキニルアルコール類 |
| GB0823002D0 (en) * | 2008-12-17 | 2009-01-28 | Syngenta Participations Ag | Isoxazoles derivatives with plant growth regulating properties |
| ES2672099T3 (es) | 2011-07-04 | 2018-06-12 | Irbm - Science Park S.P.A. | Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal |
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| MX385788B (es) * | 2015-03-04 | 2025-03-18 | Vanda Pharmaceuticals Inc | Método de tratamiento con tradipitant. |
| US10287287B2 (en) | 2015-08-17 | 2019-05-14 | Eli Lilly And Company | Process development of a pyridine-containing NK-1 receptor antagonist |
| ME03794B (me) | 2016-05-31 | 2021-04-20 | Kalvista Pharmaceuticals Ltd | Derivati pirazola kao inhibitori kalikreina plazme |
| GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| WO2019055225A1 (en) | 2017-09-13 | 2019-03-21 | Vanda Pharmaceuticals Inc. | ENHANCED TREATMENT OF ATOPIC DERMATITIS USING TRADIPITANT |
| FI3710000T3 (fi) | 2017-11-17 | 2025-07-03 | Vanda Pharmaceuticals Inc | Tradipitantti käytettäväksi gastropareesin hoidossa |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| DK3716952T3 (da) | 2017-11-29 | 2022-03-14 | Kalvista Pharmaceuticals Ltd | Doseringsformer omfattende en plasmakallikrein-inhibitor |
| CN111918647A (zh) | 2018-02-26 | 2020-11-10 | 圣拉斐尔医院有限公司 | 用于治疗眼痛的nk-1拮抗剂 |
| JP7410137B2 (ja) * | 2018-06-08 | 2024-01-09 | バンダ・ファーマシューティカルズ・インコーポレイテッド | トラジピタントを用いる処置方法 |
| US10821099B2 (en) | 2018-09-28 | 2020-11-03 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
| WO2020069092A1 (en) * | 2018-09-28 | 2020-04-02 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
| EP3890735A1 (en) | 2018-12-03 | 2021-10-13 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| WO2020132513A1 (en) | 2018-12-21 | 2020-06-25 | Vanda Pharmaceuticals Inc. | Improved treatment of atopic dermatitis with tradipitant |
| WO2021028645A1 (en) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| AU2021227900A1 (en) | 2020-02-25 | 2022-09-15 | Vanda Pharmaceuticals Inc. | Improved treatment of atopic dermatitis with tradipitant |
| EP4117673A1 (en) | 2020-03-11 | 2023-01-18 | Ospedale San Raffaele S.r.l. | Treatment of stem cell deficiency |
| EP4125811A1 (en) | 2020-03-26 | 2023-02-08 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
| US20230190740A1 (en) | 2020-04-03 | 2023-06-22 | Nerre Therapeutics Limited | An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods) |
| CN113563306B (zh) * | 2020-04-28 | 2022-07-01 | 新发药业有限公司 | 一种2-(4-苯氧基苯基)-6-(哌啶-4-)基烟酰胺的制备方法 |
| EP4157270A1 (en) | 2020-06-02 | 2023-04-05 | NeRRe Therapeutics Limited | Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs |
| CN111662235B (zh) * | 2020-06-23 | 2023-12-22 | 黄淮学院 | 一种苯甲酰基哒嗪衍生物及其制备方法 |
| WO2023019084A1 (en) | 2021-08-12 | 2023-02-16 | Vanda Pharmaceuticals Inc. | Treatment of gastric accommodation with tradipitant |
| US20240350469A1 (en) | 2021-08-31 | 2024-10-24 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
| EP4637766A1 (en) | 2022-12-21 | 2025-10-29 | Vanda Pharmaceuticals Inc. | Methods of treatment with tradipitant |
| CN116082253B (zh) * | 2023-02-25 | 2025-04-25 | 浙大城市学院 | 一种1-n-取代的1,2,3-三唑-4-甲酰胺衍生物及其制备方法 |
| WO2024223617A1 (en) * | 2023-04-24 | 2024-10-31 | Fundamental Pharma Gmbh | Effective means to modulate nmda receptor-mediated toxicity |
| US20250255855A1 (en) | 2024-02-09 | 2025-08-14 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL50699A0 (en) | 1975-10-28 | 1976-12-31 | Ici America Inc | Triazole derivatives |
| WO1995011880A1 (en) * | 1993-10-27 | 1995-05-04 | Merck Sharp & Dohme Limited | Substituted amides as tachykinin antagonists |
| US6175013B1 (en) * | 1994-06-10 | 2001-01-16 | Eli Lilly And Company | Imidazolinyl tachykinin receptor antagonists |
| US5998444A (en) | 1995-10-24 | 1999-12-07 | Zeneca Ltd. | Piperidinyl compounds as NK1 or NK2 antagonists |
| AU2633897A (en) | 1996-04-19 | 1997-11-12 | Novo Nordisk A/S | Solid phase and combinatorial synthesis of substituted 1,2,3-triazoles and of arrays of substituted 1,2,3-triazoles |
| DK0915880T3 (da) | 1996-07-24 | 2008-02-11 | Bristol Myers Squibb Pharma Co | Azolotriaziner og pyrimidiner |
| US6060478A (en) * | 1996-07-24 | 2000-05-09 | Dupont Pharmaceuticals | Azolo triazines and pyrimidines |
| EP1005454A4 (en) | 1997-08-06 | 2003-01-15 | Lilly Co Eli | 2-ACYLAMINOPROPANAMINE FOR USE AS TACHYKININ RECEPTOR ANTAGONISTS |
| ES2258485T3 (es) * | 1999-12-17 | 2006-09-01 | Schering Corporation | Antagonistas selectivos de neuroquinina. |
| TWI287003B (en) | 2000-07-24 | 2007-09-21 | Hoffmann La Roche | 4-phenyl-pyridine derivatives |
| DE10036818A1 (de) * | 2000-07-28 | 2002-02-07 | Solvay Pharm Gmbh | Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten |
| JP2002123925A (ja) | 2000-10-13 | 2002-04-26 | Fuji Photo Film Co Ltd | 磁気記録媒体 |
| DK1501808T3 (da) * | 2002-04-26 | 2008-10-13 | Lilly Co Eli | Tachykininreceptor-antagonister |
-
2003
- 2003-04-22 PT PT03723929T patent/PT1501809E/pt unknown
- 2003-04-22 PE PE2003000400A patent/PE20040600A1/es not_active Application Discontinuation
- 2003-04-22 NZ NZ535886A patent/NZ535886A/en not_active IP Right Cessation
- 2003-04-22 PL PL373504A patent/PL212090B1/pl unknown
- 2003-04-22 UA UA20041008646A patent/UA79113C2/uk unknown
- 2003-04-22 KR KR1020047017206A patent/KR100755577B1/ko not_active Expired - Lifetime
- 2003-04-22 MY MYPI20031515A patent/MY141559A/en unknown
- 2003-04-22 DE DE60318697T patent/DE60318697T2/de not_active Expired - Lifetime
- 2003-04-22 WO PCT/US2003/010681 patent/WO2003091226A1/en not_active Ceased
- 2003-04-22 AR ARP030101377A patent/AR039329A1/es unknown
- 2003-04-22 AU AU2003230829A patent/AU2003230829B8/en not_active Expired
- 2003-04-22 EP EP03723929A patent/EP1501809B1/en not_active Expired - Lifetime
- 2003-04-22 BR BRPI0309534A patent/BRPI0309534B8/pt not_active IP Right Cessation
- 2003-04-22 ES ES03723929T patent/ES2298513T3/es not_active Expired - Lifetime
- 2003-04-22 US US10/512,249 patent/US7320994B2/en not_active Expired - Lifetime
- 2003-04-22 HR HRP20041008AA patent/HRP20041008B1/hr not_active IP Right Cessation
- 2003-04-22 CN CNB038091046A patent/CN1312136C/zh not_active Expired - Lifetime
- 2003-04-22 AT AT03723929T patent/ATE384053T1/de active
- 2003-04-22 EA EA200401431A patent/EA007720B1/ru not_active IP Right Cessation
- 2003-04-22 JP JP2003587786A patent/JP4559087B2/ja not_active Expired - Lifetime
- 2003-04-22 MX MXPA04010622A patent/MXPA04010622A/es active IP Right Grant
- 2003-04-22 TW TW092109375A patent/TWI265807B/zh not_active IP Right Cessation
- 2003-04-22 CA CA2483159A patent/CA2483159C/en not_active Expired - Lifetime
- 2003-04-22 DK DK03723929T patent/DK1501809T3/da active
-
2004
- 2004-10-18 IL IL16467504A patent/IL164675A0/xx not_active IP Right Cessation
- 2004-10-25 CR CR7548A patent/CR7548A/es unknown
- 2004-10-26 ZA ZA200408670A patent/ZA200408670B/xx unknown
- 2004-10-26 EC EC2004005391A patent/ECSP045391A/es unknown
- 2004-11-24 NO NO20045120A patent/NO333647B1/no not_active IP Right Cessation
-
2008
- 2008-02-28 CY CY20081100235T patent/CY1107221T1/el unknown
-
2009
- 2009-04-07 IL IL198122A patent/IL198122A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0309534B8 (pt) | derivados de triazol como antagonistas do receptor de taquicinina, seu uso, e composição farmacêutica | |
| BR0308146A (pt) | Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto | |
| BR0213790A (pt) | Derivados de aminobenzamida como inibidores de glicogênio sintase cinase 3beta | |
| MA31574B1 (fr) | Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf | |
| BR0308145A (pt) | Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto | |
| HRP20090162T1 (en) | Quinolinone-carboxamide compounds as 5-ht4 receptor agonists | |
| BR0214455A (pt) | Derivados benzotiazol | |
| HRP20020175B1 (hr) | N-heterociklički derivati kao inhibitori nos | |
| MY136959A (en) | Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof | |
| BR0002515A (pt) | Derivados de 4-arilpiperidina para o tratamento do prurido | |
| BR9907300A (pt) | Inibidores do fator xa oxoaza-heterociclila substituìdos | |
| WO2008002596A3 (en) | Adenosine a2a receptor antagonists | |
| EA200300453A1 (ru) | Производные 3-ароилиндола и их применение в качестве агонистов рецепторов cb2 | |
| AR037682A1 (es) | Derivados de acetileno que tienen actividad antagonista para receptores glutamato metabotropico humanos, composicion farmaceutica, una combinacion y el uso de dichos derivados para la fabricacion de composiciones farmaceuticas | |
| BRPI9913542B8 (pt) | derivados de dihidrobenzodioxina carboxamida e dihidrobenzodioxina cetona como antagonistas do receptor 5-ht4 bem como composição farmacêutica, processo para a preparação dos referidos derivados e uso dos mesmos | |
| BRPI0507495A (pt) | composto, composição farmacêutica, uso do composto método para o tratamento de distúrbios mediados por mglur5, e, método para inibir a ativação de receptores de mglur5 | |
| NO20051051L (no) | Derivater av dioksan-2-alkylkarbamater, fremgangsmate for fremstilling derav og anvendelse av de samme i terapeutiske midler | |
| BR0308144A (pt) | Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto | |
| TW200640916A (en) | (1,5-diphenyl-1H-pyrazol-3-yl)oxadiazole derivatives, their preparation and their application in therapeutics | |
| WO2005003087A3 (en) | Oxazole derivatives as antibacterial agents | |
| DE60330758D1 (de) | Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen | |
| MXPA04006113A (es) | Derivados de triazoloquinolina utiles como ligandos receptores de adenosina. | |
| WO2008155588A8 (en) | Sulfonyl-quinoline derivatives | |
| AR054707A1 (es) | Derivados de octahidropirrolo 3,4-c pirrol, un procedimiento para su preparacion, una composicion farmaceutica y uso del compuesto para la fabricacion de un medicamento | |
| BRPI0510397A (pt) | compostos, composições farmacêuticas contendo os mesmos, e métodos de uso dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: PARA INT.CL: C07D 249/06, C07D 401/04, C07D 4010/14, C07D 403/04, C07D 403/14, C07D 413/04, C07D C07D 417/14, C07D 487/04, C07D 498/04, A61K 31/492, A61K 31/4196, A61K 31/422, A61K 31/4439, A61K 31/427, A61K 31/497, A61K 31/501, A61K 31/05, A61P 25/00 Ipc: C07D 249/06 (2011.01), C07D 401/04 (2011.01), C07D |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/11/2017, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/04/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 22/04/2023 |